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Cultivated Vaginal Microbiomes Alter HIV-1 Infection
and Antiretroviral Efficacy in Colonized Epithelial
Multilayer Cultures
Richard B. Pyles1,2*, Kathleen L. Vincent3, Marc M. Baum4, Barry Elsom1, Aaron L. Miller1, Carrie Maxwell2,
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Abstract
There is a pressing need for modeling of the symbiotic and at times dysbiotic relationship established between bacterial
microbiomes and human mucosal surfaces. In particular clinical studies have indicated that the complex vaginal
microbiome (VMB) contributes to the protection against sexually-transmitted pathogens including the life-threatening
human immunodeficiency virus (HIV-1). The human microbiome project has substantially increased our understanding of
the complex bacterial communities in the vagina however, as is the case for most microbiomes, very few of the community
member species have been successfully cultivated in the laboratory limiting the types of studies that can be completed. A
genetically controlled ex vivo model system is critically needed to study the complex interactions and associated molecular
dialog. We present the first vaginal mucosal culture model that supports colonization by both healthy and dysbiotic VMB
from vaginal swabs collected from routine gynecological patients. The immortalized vaginal epithelial cells used in the
model and VMB cryopreservation methods provide the opportunity to reproducibly create replicates for lab-based
evaluations of this important mucosal/bacterial community interface. The culture system also contains HIV-1 susceptible
cells allowing us to study the impact of representative microbiomes on replication. Our results show that our culture system
supports stable and reproducible colonization by VMB representing distinct community state types and that the selected
representatives have significantly different effects on the replication of HIV-1. Further, we show the utility of the system to
predict unwanted alterations in efficacy or bacterial community profiles following topical application of a front line
antiretroviral.
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mucosa. Conversely, a common dysbiotic state, referred to as
bacterial vaginosis (BV), occurs when Lactobacillus-dominated
VMBs are displaced by pathogenic bacterial communities with
inflammatory properties. BV is the most common cause of vaginal
concern in adult women worldwide and represents roughly 22
million annual cases in the U.S. substantially adding to health care
costs [3,4]. Prevalence varies geographically and racially with rates
as high as 1 in 2 women [5]. Clinically BV can be asymptomatic or
include symptoms ranging from a malodorous discharge and
elevated vaginal pH to inflammation and, in severe cases, fertility
issues including pre-term labor and delivery [6]. Although still
debated, a number of studies suggest there is a sexual transmission
or enhancement component to BV acquisition [7–9] however the
mechanisms leading to BV development are poorly defined.
Established risk factors for BV include multiple sexual partners [9],

Introduction
The vaginal mucosa is composed of a stratified squamous
epithelium covered by a mucous and glycogen rich layer that
supports colonization by highly complex and remarkably diverse
bacterial communities. The symbiotic relationship between the
bacterial community fed by the carbon sources provided by the
vaginal epithelial cells (VEC) creates both physical and chemical
barriers that serve as part of the front line defenses against
infection. Doederlein and colleagues are credited with the first
report of cultivation of vaginal bacteria in 1892 exclusively
isolating Lactobacilli concluding that they were important
contributors to vaginal health [1,2]. The vaginal microbiome
(VMB) is now known to be composed of many different species of
bacteria that collaborate to enhance the health of the vaginal
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lack of male circumcision [10], hygiene (e.g. douching) [11,12],
host genetic polymorphisms [13] and others. Current antibiotic
treatments are disappointing with a high frequency of recurrence
[5] likely due to the formation of resistant biofilms that provide
effective survival niches [8]. BV biofilms have also been connected
to transmission as well as altering the success of antimicrobial
therapies to treat other sexually transmitted infections (STI) [8].
In addition to impacting antimicrobial therapy, clinical
associations have established that BV VMBs increase susceptibility
to infection by HIV-1 and other STI [14–16]. In HIV-infected
women, BV VMBs also associate with elevated HIV-1 titers in
vaginal fluids increasing the likelihood of transmission to naı̈ve
partners [17]. Global estimates suggest there are more than 34
million people infected with HIV-1 with up to 7,000 new
infections each day and almost 2 million AIDS-related deaths
annually [18,19]. Because women are more susceptible to HIV
infection than men, studies of the impact of specific species or
bacterial partnerships in healthy and dysbiotic VMB are
desperately needed. The majority of VMB bacteria have proven
impossible to cultivate in the lab and to date no in vitro or animal
model system has been reported that supports colonization by
intact healthy or BV VMB communities. The lack of such models
has severely impacted the ability to predict toxic effects of vaginal
applicants on an otherwise protective VMB.
Recent clinical reports have established that vaginal applicants
can alter VMB composition [20]. These studies have been
completed using cultivation-independent molecular approaches
that have substantially advanced our understanding of the
composition of bacterial communities leading to solidly established
associations between Lactobacilli-dominated VMB and protection
against HIV-1 and other STI [14,15,21]. Vaginal applicants,
including over the counter feminine hygiene products commonly
used to address discharge, malodor and a variety of other
concerns, are delivered by several modalities including gels,
suppositories and intravaginal rings (IVR) that likely have
differential impacts upon VMBs. These delivery methods have
been utilized for a variety of prophylactic compounds collectively
referred to as microbicides designed to provide protection against
HIV-1 [22]. It is well reported that several lead microbicides,
selected by standard efficacy testing paradigms, failed to protect
treated women from acquiring HIV-1 or other STI [23,24].
Subsequent clinical evaluations suggest that these failures may be
caused by VMB disruption leading to inflamed or unhealthy
mucosae that were actually predisposed to infection [20,25–27].
Such failures have been blamed, in part, on inadequate efficacy
and safety testing [28–30].
Cultivation-independent clinical sampling approaches including
vaginal swabs, tissue biopsies and IVR evaluations have provided
insights into VMB composition. These approaches have highlighted the dynamic and kinetically fluid interactions among VMB
community members and with the VEC but are complicated by
the genetic and environmental diversity influences that confound
interpretation of these massive data sets. Specifically, next
generation sequencing studies completed by several groups have
solidly established the complexity and dynamic nature of VMB
communities as well as the impact of race, menstruation, sampling
method, etc. [31–35]. Using sequence data from a remarkably
large cohort of women, Ravel and colleagues have suggested a
categorization scheme based on the four Lactobacillus species that
most frequently dominate healthy VMB [34]. Their system
designates VMB community state types (CST) based on the
predominance of one Lactobacillus species; L. crispatus (CST I), L.
gasseri (CST II), L. iners (CST III) and L. jensenii (CST V). VMB
with multiple Lactobacillus species rather than a single predomPLOS ONE | www.plosone.org

inant organism are categorized as CST IVA. VMB that lack
Lactobacilli and are commonly designated as BV are categorized
as CST IVB.
Using this categorization system and a PCR-based approach to
characterize cryopreserved VMB collected from women undergoing routine gynecological exams, we have extended our recently
reported VEC stratified multilayer culture system [36] to show
reliable colonization by intact VMB representing 5 of the 6 CST; a
CST V VMB that met our inclusion criteria was not available in
our current repository preventing its inclusion in these studies. The
cultured VEC multilayers recapitulate key aspects of the vaginal
mucosa including production of the necessary carbon sources and
molecular signals to support the bacterial communities. This
culture model supported the formation of VMB-associated
biofilms that, in turn, altered the culture phenotype with regard
to HIV-1 infection and topical antiretroviral therapy. For study of
HIV-1 infection, the multilayer cultures were refined to include
HIV-1 susceptible cells that allowed a controlled environment free
of the clinical confounders to address reliably reproduced VMB
that significantly altered HIV-1 infection and/or replication. This
represents the first system to study lab-cultivated VMB thereby
providing the opportunity to establish impact on STI outcomes
and to better predict safety and efficacy of vaginal applicants.

Results
Vaginal epithelial cell (VEC) multilayer co-culture
susceptible to HIV-1 infection
We previously reported the establishment of a stratified
squamous VEC multilayer culture system with an apical airinterface that produces the necessary carbon sources for colonization by several single species commensal bacteria common to
the vagina [36]. To study the impact of complex bacterial
community types upon HIV-1 infection we modified the cultures
to include cell types susceptible to HIV-1 infection. Two types of
HIV-1-susceptible cells were selected for evaluation and optimization. TZM-bl cells, derived originally from HeLa cells by
transgenic addition of human CD4 (the primary HIV-1 receptor)
and CCR5 (HIV-1 coreceptor) and an HIV-1 Tat responsive bgalactosidase (b-gal) reporter system [37–39], were selected based
on the cervical tissue origin of HeLa cells and their promiscuous
growth conditions. Primary human monocyte-derived macrophages (MDM) were selected as the second susceptible cell type to
allow study of a natural HIV-1 target cell that was fully competent
for immune responses. Macrophages are also common to vaginal
tissues suggesting the potential for co-culture with the VEC [40].
Media and culture conditions were optimized for the co-cultures in
both 24 and 96 transwell formats. The 96 well format provided the
opportunity for medium throughput analyses essential to future
drug screening or advanced study designs.
The presence of HIV-1 susceptible cells did not alter multilayer
formation based upon morphology and thickness shown by
hematoxylin and eosin (H&E) staining (Fig. 1A, TZM-bl & H,
MDM). Labeling of co-culture multilayer sections with anti-CD4
antibodies showed the periodic distribution of the co-cultured
CD4+ TZM-bl cells (Fig. 1B) in the VEC multilayer (Fig. 1B & C).
VEC-TZM-bl wells infected with HIV-1SX-1 (an R5 strain that
infects through CD4 and the CCR5 coreceptor expressed on both
TZM-bl and MDM) were stained with X-gal (48 h pi) to localize
b-gal+ cells. In situ X-gal staining of infected cultures provided the
opportunity to identify the number and size of HIV-1 replication
foci (Fig. 1D–G). Uninfected cultures showed no evidence of any
blue deposition.
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Figure 1. Refined vaginal epithelial multilayer co-cultures that support HIV-1 infection. Optimized conditions for establishment of cocultures that contain HIV-1 susceptible cells are illustrated in panels A–J. Panels A–G represent outcomes with VEC/TZM-bl co-cultures as indicated by
H&E staining of 6 um sections (A) or immunolabeling of a section showing the presence of CD4+ TZM-bl cells (B, arrows indicate positive cells) in the
context of VEC labeled with cytokeratin and DAPI (C). TZM-bl cells provided a b-gal reporter system to detect HIV-1 infection via staining with X-gal
(blue precipitate) as shown in panels D–G. Panel D shows X-gal localization of HIV-1 infection (blue box) of an uncolonized culture while E–G illustrate
cultures apically colonized with clinical VBM (CSTI, CSTIII and CSTIVB, respectively). Co-cultures with primary human MDM were established as
illustrated by H&E staining (H), CD4 immunolabeling ((I); green cells indicated by arrows are MDM) in the context of cytokeratin and DAPI labeled VEC
(J). HIV-1SX infection was evaluated over time in triplicate multilayer VEC/TZM-bl (K) or VEC/MDM co-cultures (L). The transwell culture system
provided sampling of each chamber (apical in blue, cell fraction in black and basal chamber in red) representing different aspects of the viral infection
process.
doi:10.1371/journal.pone.0093419.g001

three compartments associated with HIV-1 infection. Specifically,
the co-culture apical surface was subjected to gentle lavage to
collect virus associated with female to male transmission, the cell
fraction was harvested to quantify active viral replication and
integration and, finally, the basal compartment was sampled to
measure virus that transcytosed the multilayer modeling potential
spread to systemic sites. Samples were analyzed by HIV-specific
quantitative RT-PCR from each compartment harvested at 24,
48, or 72 h pi. The initial inoculum of 1,000 TCID50 of HIV-1SX1 (MOI of 1) led to increased genomic titers with lower amounts of
virus produced in both apical and cellular fractions from VECTZM-bl co-cultures than was detected in VEC-MDM transwells
infected in parallel (Fig. 1K & L, respectively). No virus was
detected in the basal chamber of either co-culture until 48 h pi
confirming the multilayer integrity. These results led us to select
48 h of infection for the future studies of the cellular fraction and
confirmed the utility of both co-culture systems for study of HIV-1
infection.

MDM offered many advantages for study of natural HIV-1
infection including important signaling pathways active in these
professional immune cells that are inactive in TZM-bl cells. For
this reason, VEC-MDM co-cultures were also optimized and
evaluated as shown for VEC TZM-bl (Fig. 1H–J). For both coculture systems, the ratio of HIV-1 susceptible cells to VEC plated
in the transwells (1:1000) was based on published estimates of
normal and inflamed vaginal tissues [40] and ultimately was
selected based on optimal infection outcomes for subsequent
evaluations of HIV-1 replication. The data indicated that under
the optimized culture conditions both TZM-bl and MDM
established ‘‘tissue’’ niches that led to at least 14 d of viability.
TZM-bl cells expanded into clusters but the MDM remained as
single cells in the multilayers.
Basic viral replication kinetic profiles were established by
delivery of the inoculum to the apical surface of mature multilayer
co-cultures (d7 post plating) simulating vaginal exposure to HIV-1.
The transwell system also provided for the opportunity to model
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magnification the presence of extracellular polymeric substances
coating dense areas of mixed morphotypes of bacteria indicative of
biofilm formation at 48 and 72 h after colonization (Fig. 2C,
bottom right). Collectively these data provided two essential
outcomes. First, the kinetic assessments confirmed that an
optimized cryopreservation method was established that preserved
viable diversity of the VMB communities allowing for repeated
study of the same VMB. As shown in Table 1, all of the outgrowth
profiles fell into the same CST as the original inoculum however,
there were some noted diversity changes as described below. The
current data suggest that stable cryopreservation of at least 5 years
is possible. The second important outcome was apical application
of VMB samples confirmed that the VEC co-culture multilayers
were capable of supporting colonization by these complex
bacterial communities in reproducible fashion (n$3 studies).
Importantly, these cultures provided the first lab-based cultivation
of many of the bacterial species previously only studied by
cultivation-independent methods including the bacterial vaginosisassociated bacteria (BVAB) species and several other anaerobic
species.
To identify limitations of the VEC culture system, we evaluated
colonization by multiple VMB looking for specific genus or
species-level community members that consistently failed to
increase in titer. The vast majority of identified community
members increased or maintained genomic titers relative to the
levels predicted by the original inoculum (Table 1). In fact, several
bacterial species undetected in the inoculum were detected after
48 h of colonization (e.g. Peptinophilus spp, group B streptococcus,
Aerococcus spp, Dialister spp, and A. vaginae) suggesting that for such
bacteria, the VEC multilayer provided a potentially enhanced
environment relative to the vaginal mucosa. Similarly, a few
bacteria maintained or had slightly lower titers or were lost from
the population at 48 h in a community dependent fashion (Table 1;
e.g. Prevotella buccalis-like, Cloacibacterium spp and Proteobacteria spp).
Unexpectedly, in the tested CST III VMB, L. crispatus failed to
thrive in contrast to our data from single species colonization [36].
We also assessed the inflammatory state established by each of
the CST representatives and as previously observed with
commensal single species [36], no detectable increase in secreted
cytokines in apical washes or in cell fractions from VEC cocultures colonized was produced by any CST other than the III or
IVB representatives (Table 2). Colonization with a CST III or IVB
representative led to significant increases in IL-1b, IL-8, TNFa,
RANTES and IL-1ra (Table 2). There was a notable but not
significant trend for the CST I and II representatives to reduce
baseline secretion of selected cytokines consistent with our
previously reported findings with single Lactobacillus spp colonization [36].

VEC co-cultures supported clinical vaginal microbiome
(VMB) colonization
We previously reported that the air-interfaced, apical surface of
VEC multilayers could be colonized with lab-cultivated, single
species bacteria and that colonization altered cytokine secretion
induced by challenge with selected TLR agonists [36]. To
determine if matured VEC-TZM-bl and VEC-MDM co-culture
multilayers could support colonization by intact VMB we collected
mid vaginal swab samples from asymptomatic patients undergoing
routine gynecological examinations. Swabs were collected into
sterile PBS after consent of the participant and then sterilely
processed and cryopreserved in small aliquots. Each sample was
evaluated for Nugent score (NS), Amsel’s criteria and then
categorized molecularly into a CST [34]. Molecular evaluations
were completed using a novel PCR array that provided
quantitative estimations of 40 of the most relevant bacterial
species or genetic elements necessary for CST profiling and BV
state evaluation (Table 1). Samples that were found to contain an
STI including, Chlamydia trachomatis, cytomegalovirus, herpes
simplex virus, human papilloma virus, Mycoplasma genitalium,
Neisseria gonorrhea, Trichomonas vaginalis, Ureaplasma spp or detectable
yeast (Candida spp) were excluded from additional study. Finally, as
indicated by PCR detection of the presence of Y chromosome
sequences, samples from women who had recent sexual intercourse also were excluded. Using these criteria, seven VMB
representing 5 of the 6 CST and a range of NSs were selected for
testing (Table 1).
Aliquots of the selected samples were thawed and tested for
general bacterial viability by creating a 10-fold dilution series in
Mann-Ragosa Sharpe (MRS) broth to quantify bacterial titer [36].
Using optimized cryopreservation methods, viable bacteria were
observed at titers of ,105–108/ml in the thawed samples and were
similar to the titers established in the freshly collected, original
swab sample. We next evaluated whether these cryopreserved
VMB samples could be used to colonize the apical surface of
established VEC multilayer cultures. Thawed samples were
diluted 1,000- to 100,000-fold in PBS and apically applied to
mature co-cultures and molecularly followed for increases in
bacterial titers and preservation of community diversity (Table 1).
The target inoculum, based on total bacterial genomic load
measured by 16s rDNA qPCR, was 1,000–5,000 bacterial
genomes. The data, summarized from three distinct studies,
showed reproducible community establishment for each of the
selected CST independent of the type of co-cultured multilayer
(Table 1). Uncolonized cultures were prepared in parallel for every
study and consistently tested negative for any bacteria. It is notable
that several previously uncultivated bacterial species (e.g. BVAB
species, CST IVB NS8) were propagated in this format.
Additionally, in the context of complex VMB populations, L. iners
colonized the VEC co-cultures (e.g. CSTs I, III and IVA) in
contrast to our previous inability to viably colonize multilayers
with this single species [36]. Consistent with these collaborative
interactions, the colonized multilayer cultures supported many
species of anaerobic bacteria in the 5% CO2 supplemented normal
air environment consistent with the natural environment created
in the human vagina.
Two VMB communities of intermediate (CST III, NS2) and
extreme population diversity (CST IVB, NS8) were selected to
illustrate the quantitative increase in multiple species as shown
Table 1 and as depicted graphically in Fig. 2A & B, respectively. In
parallel with the molecular evaluations, colonization by the highly
complex CST IVB VMB was followed kinetically by scanning
electron microscopy (SEM) to visualize the increases in both total
bacterial number and morphotypes (Fig. 2, 16–72 h). At higher
PLOS ONE | www.plosone.org

VMB altered HIV-1 titers showing both suppressive and
enhancing communities could be identified
Based on the successful colonization of VEC co-cultures and
successful HIV-1 infections of the co-cultures, we tested the
hypothesis that colonization by the VMB CST representatives
would alter HIV-1 infection/replication as indicated by genomic
titers in the cellular fractions. Three replicate studies were
completed and the outcomes are presented as average HIV-1
genomic burden in the context of uncolonized or specifically
colonized VEC co-cultures established with either TZM-bl or
MDM (Fig. 3A and B, respectively). For the first studies in VECTZM-bl cultures, poly-inosine:cytidylic acid (poly-IC) was applied
to uncolonized multilayers 16 h before HIV-1 infection to
enhance HIV-1 replication relative to untreated, uncolonized
control cultures (Fig. 3A red bar vs. white bar, respectively).
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Table 1. Quantified genomes of selected bacteria in representative VMB communities in colonized VEC multilayer cultures relative
to the inocula.

TARGET

CST I (NS0)

CST II (NS1)

CST III (NS2)

CST III (NS5)

CST IVA (NS5) CST IVB (NS8)

CST IVB (NS8)

Inoc 48 h

Inoc 48 h

Inoc 48 h

Inoc 48 h

Inoc 48 h

Inoc 48 h

Inoc 48 h

Human GAPDH

4

6.365.6

2.38

6.866.6

6.961.5

4.21

6.565.9

7.167

2.99

6.566.3

Total bacteria (16S)

6.06

6.165.9

6.26

7.0366.1

7.86

8.964.9

5.82

7.367.3

7.8

8.0463.1

7.86

8.9964.6

7.83

8.467.4

Lactobacillus spp

4.22

5.3565.3

2.23

5.4564.3

6.65

7.8567.4

4.06

7.1765.6

5.5

5.7565.6

2.79

4.9463.9

3.81

6.6365.6

L. crispatus

5.04

5.0664

6.68

4.8464

4.8

5.5964.8

4.66*

6.9666.2

5.04

5.365.1

2.39*

5.764.8

3.74

3.4862.8

3.7462.8

3.08

3.2462.4

L. gasseri

3.85

L. iners

3.66

4.1763.1

L. jensenii

2.78

4.4163.6

L. fermentum
Acidovorax

3.1363

2.21

3.7763.5

5.2764.5

5.8664.9
5.29

2.59

3.7763.6

2.53

3.562.8

3

3.6462.1

3.7

Aerococcus

Atopobium vaginae

5.865.1

4.87*

4.6663.8

362.94

3.7663.9

3.9463.9

3.5662.7

2.7

4.3263.25

6.7365.7

4.9563.5

6.4966

4.13

5.7064.7

BVAB1

4.1

5.5764.5

BVAB2

4.1

4.9364.6

BVAB3

4.0

4.263.9

BVAB-TM7
Cloacibacterium
Corynebacterium

2.0961.9
3.71

4.0463.9

1.4

2.74

3.0162.1

4.2262.6

Dialister

3.7

2.863

2.51

4.11

5.2464.2

4.45

3.73*

E. coli

1.6361.5

2.7

4.5263.4

2.94

3.7763.6

4.5462.4

4.1

4.9564.8

3.4*

2.34

2.761.6

2.6462.8

2.96

4.2363.9

3.0663

Eggerthella-like
Enterococcus

6.4265.6
4.1863.9

3.7863.3
3.84

3.3762.2

2.27

2.5661.7

5.92

564.2

3.43

3.4363.2

3.24

463.9

4.1

7.4366.5

Gardnerella vaginalis

6.11*

7.1266.6

4.1

7.166.2

G. vaginalis sialidase

5.764

5.9465.9

4.1

6.1266

Haemophilus

4.1463.8

1.64

1.2460.4

3.7563.1

4.0863.6

Lachnospiraceae

4.81

Leptotrichia amnionii

3.64*

1.16

3.9364

2.7761.6

3.7463.5

3.2263.1

3.9

2.0661.9

3.8963.3

4.4

Megasphaera Type 1

5.4264.4

Mobiluncus mulieris

4.1

Mycoplasma hominis

5.6864.6
4.4363.7

2.11*

4.7663.7
1.37*

Parvimonas

3.4463.1

Peptoniphilus lacrimalis

2.67*

4.763.7

Peptoniphilus

2.81*

4.564.3

Peptostreptococcus

3.8963.6

Prevotella buccalis-like

4.1

Prevotella G1
Prevotella

3.86*

Proteobacteria a, b

2.01

Proteobacteria b, g

2.26

3.14*
4.664.4

Ruminococcaceae

1.3*

Sneathia sanguinegens

4.11*

4.26
3.1

3.663.7

4.10

6.2765.6

3.363.1

4.7164.5

3.54

3.7563.7

4.15

3.563.3

4.664.5

3.93

4.664.5

3.32*

3.88

4.32

4.2460.1

5.06

4.663.5

4.160.1

4.02

3.5662.8

3.31*
4.61*
4.0663.9

4.3364.2

3.53

3.18

Staphylococcus

Streptococcus

2.4762.3
4.163.3

4.06

3.9564.1

4.08*

Group B Streptococcus

Veillonella

3.563.3
2.8862.6

2.62

3.2163.3

4.3263.9

3.8

5.4764.5
3.81

7.4166.6

3.863.7

3.63*

3.53*

3.49

6.4466.2

5.05

5.6265.5

665.6

3.33

5.8665.6

3.0462.8

665.3
6.2266
1.8461.6

3.4

4.764.6
3.2262.3

The log10 average genomic count (N = 6–9) established by qPCR for the indicated bacterial genus or species 6 the standard error of the mean are depicted. Empty cells
indicate a lack of detectable target DNA in each sample. Values marked by ‘‘*’’ indicate only a single positive value was detected among the sampled cultures in that
group. A portion of each undiluted inocula (inoc) of roughly equivalent volume was quantified in parallel to the bacterial levels present 48 h after colonization of the
matured VEC multilayers.
doi:10.1371/journal.pone.0093419.t001

PLOS ONE | www.plosone.org

5

March 2014 | Volume 9 | Issue 3 | e93419

Cultivated Vaginal Microbiomes Alter HIV-1 Infection

Figure 2. VMB colonization of VEC/TZM-bl multilayer co-cultures recreated the complex bacterial communities present in clinical
samples. To confirm that the environment created by VEC multilayer cultures could support colonization by in tact VMB, established cultures in 96
well format (N$6/time point) were inoculated apically with ,1,000 bacterial genomes and followed kinetically by qPCR (A and B). A representative
VMB of CST III (Nugent score, NS 2) and a CST IVB (NS8) types are depicted to illustrate that overall bacterial load (blue line) increased over the 64 h
evaluation with a coincident increase in host genomes (black line) indicating culture health. In both graphs, green lines represent bacteria associated
with healthy vaginal status and red lines are considered pathogenic. Quantified data for the bacteria targeted by the qPCR from these and other
representative VMB are presented in Table 1. The lower panels depict SEM evaluations of a set of parallel cultures (2/time point) colonized by a CST
IVB VMB with community diversity. Colonized cultures were fixed at the indicated times and visualized to illustrate the increasing number and
diversity of bacterial morphotypes as well as the production of extracellular polymeric substances coating and connecting individual bacteria (lower
right panel).
doi:10.1371/journal.pone.0093419.g002

Poly-IC significantly increased HIV-1 genomic titers in treated
cultures (p,0.05) and provided an indication of potential
enhancement of viral replication in the co-culture system. As
indicated by the blue bars (Fig. 3A), genomic titers, similar to those

PLOS ONE | www.plosone.org

in Poly-IC-treated co-cultures, were produced in VMB with higher
NS (CST III, IVA and IVB). Consistent with the data shown in
Fig. 1, VEC-TZM-bl co-cultures produced less HIV-1 than VECMDM co-cultures (Fig. 3A vs. B) but following VMB colonization
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Table 2. Cytokine secretion from VECMDM multilayers colonized with selected bacteria or VMB CST.

Cytokine

No bacteria

L. crispatus

CST I (NS0)

CST II (NS2)

CST III (NS5)

CST IVB (NS8)

IL-1b

9.260.4

a

2.360.6

0.960.4

4.860.8

40.6613.9*

112.4618.3*

IL-6

0.260.02

1.360.5

0.360.1

0.360.1

11.962.4

3.561.2

IL-8

4.160.8

5.961.6

6.862.4

7.763.9

194634*

45606808*

TNFa

5.360.9

7.862.5

10.562.7

5.161.1

3106119*

158.7648.9*
86.365.2

G-CSF

24.562.5

27.663.4

28.168.2

25.765.2

35.963.2

GM-CSF

6.662.3

2.960.5

2.360.6

12.765.8

2.961

47.6611.7

RANTES

1060.8

4.460.8

2.560.8

1.760.5

45.1611.1*

52.365.1*

IL-1ra

7686319

494.7642.3

5766149

590669

45946761*

649361671*

Single species bacteria or representative VMB’s were inoculated on the apical surface of mature VECMDM multilayers at ,1000 genomes. Cell fraction sampling was
completed at 48 h after colonization.
a
Selected cytokines are presented as mean+SEM (pg/ml) of 3 replicates from 2 independent studies.
*p,0.05 compared to no bacteria (Student’s t-test).
doi:10.1371/journal.pone.0093419.t002

Interestingly, the second CST III community (NS5), collected
,60 d earlier from the same woman as the most suppressive
VMB, showed a distinct community profile that was dominated
again by L. iners and group B streptococcus but included at least 4
additional bacterial species that contributed to enhanced HIV-1
replication (p,0.05, Fig. 3). These bacteria included Ruminococcaceae spp, Aerococcus spp, Sneathia sanguinegens and Atopobium vaginae
(Table 1). These organisms were present at similar or higher levels
in the CST IVB community that also produced significantly
higher HIV-1 levels relative to uncolonized controls (p,0.05).
Comparisons of the two VMB that significantly enhanced HIV-1
genomic titers to those produced in each of the CST I, CST II
VMB or single species colonized co-cultures (green bars) also were
significantly different (p,0.05). Of the 4 bacteria common to the
HIV-1 enhancing communities, CST I and CST II communities

extremely similar patterns of viral burden were observed in a
community-dependent fashion. Both types of co-culture indicated
that, relative to uncolonized cultures, one of the two selected CST
III communities (containing at least 17 distinct community
members dominated by L. iners and group B streptococcus;
Table 1) significantly suppressed HIV-1 replication (Fig. 3,
p,0.05). Similarly, although not significantly different from
uncolonized cultures, HIV-1 levels in all of the CST I, CST II
VMB or single species Lactobacilli-colonized VEC-TZM-bl and
VEC-MDM co-cultures trended lower indicating HIV-1 suppression associated with these bacteria. Additional confirmation was
provided by X-gal staining of infected, colonized VEC-TZM-bl
co-cultures that showed small foci (Fig. 1E) relative to VMB that
produced higher HIV-1 burdens (Fig. 1F and G).

Figure 3. HIV-1 burden was significantly altered by VMB colonization of VEC multilayer co-cultures. To directly study the impact of
representative VMB upon HIV-1 infection and replication VEC/TZM-bl (A) or VEC/MDM (B) co-culture multilayers were established in 96 well format.
Matured cultures were colonized and virally challenged as described in the methods. Representative healthy (dark green bars) or pathogenic (blue
bars) VMB, single species bacteria or the probiotic Lactobacilli mixture (light green bars) are indicated on the x-axes. Mean genomic HIV-1 titer is
shown on the y axes. Statistical comparisons were completed by one-way ANOVA with Bonferroni’s or Dunnett’s multiple comparison correction. A
‘‘*’’ indicates a significant difference (P,0.05) relative to the uncolonized viral burden. A ‘‘#’’ indicates a significant difference (P,0.05) with the
suppressive CST III VMB. Triplicate cultures were created and the study was replicated twice. Poly-I:C (0.1 mg/ml) was utilized as an inducer of HIV-1
infection and replication and was applied at the time of colonization.
doi:10.1371/journal.pone.0093419.g003
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had lower but detectable levels of Ruminococcaceae spp, S. sanguinegens
and Atopobium vaginae (Table 1). Aerococcus spp was the only identified
bacteria absent from the suppressing VMB types (Table 1). Study
of additional community representatives for each CST will be
required to complete comprehensive associations but at present
these data indicate the utility of the model system and establish the
potential for subsequent evaluations of additional clinical samples.

application of TFV treatment was associated with increased levels
of Aerococcus spp, A. vaginae, the BVABs, and G. vaginalis.
Paradoxically, the amount of G. vaginalis sialidase DNA was
reduced. Collectively, these preliminary studies suggest the VMB
colonized multilayer co-culture model will be of substantial use for
prediction of vaginal applicant impact upon the VMB but
additional association with clinical data will be required.

Multilayer colonization by VMB impacted tenofovir (TFV)
efficacy and illustrated unexpected alterations in the
VMB composition

Discussion
There has been a pressing need to develop a model system to
study the intact VMB in the context of VEC and professional
immune cells. Since the earliest descriptions of the bacteria that
colonized the human vagina there have been many efforts to
cultivate the complex communities in the laboratory. Recent
success with cultivation-independent approaches has established
an accurate picture of the community members and the impact of
external influences upon the VMB [20,31,33,34,44] but each of
these studies has been complicated by the genetic diversity of the
human participants and the nature of the sampling. These factors
have substantially impacted the development of statistical power
thereby limiting the quality of the conclusions. We present the
results from a combination of recent advances in cell culture
systems that create more accurate models of the vaginal mucosa
[36] with methods to molecularly evaluate and reproducibly
propagate intact vaginal communities recovered from vaginal
samples collected during routine gynecological exams. The system
provides the first lab-based opportunity to begin the study of the
important species or partnerships between species in both healthy
and dysbiotic VMB.
Our VEC multilayer culture system provides the necessary
environment to support colonization by intact, transplanted VMB
representing 5 of the 6 established CST (Table 1). The current
data indicate that VMB established in our cultures retained the
general character of the VMB detected in the clinical inocula but
there were noted differences in some bacterial levels. In some
cases, these differences are most explained by a lower than
detectable level of specific bacteria in the inoculum that expanded
in the favorable environment created by the VEC multilayer.
Conversely, as shown by the representative CST III (NS5) and
IVB VMBs several community shifts (e.g. L. iners) could be seen
consistently in the established VMB. Further studies will be
required to evaluate the impact of such differences that have been
widely reported in clinical studies of the same woman over time
(20, 33, 34). The reproducibility of the established VMB indicates
the utility of the culture system but may reveal a limitation of the
cultures with regard to certain community profiles. Further CST
representatives will need to be tested to more fully validate the
VEC multilayer system.
Cryopreservation of the VMB sample allowed for repeated
analyses and development of mechanistic studies to understand the
relationships formed between bacterial community members and
between the VMB and the underlying host cells. This was
completed in a defined genetic background provided by the
immortalized VEC and controlled culture conditions. Further, the
model provides opportunity for controlled introduction of
influences that would not be possible in clinical research settings.
The refinement provided by the established co-cultures also
enables the opportunity to begin to study the molecular dialogs
between professional immune cells common to the vaginal mucosa
and the surrounding VEC in the context of controlled colonization
by selected VMB. Such studies will include evaluation of the
metabolome and signaling molecules common to each VMB. Two
elegant clinical evaluations were recently reported showing the

Clinically, VMB appear to alter the efficacy of vaginally-applied
antiretroviral compounds through unknown mechanisms. Conversely, molecular evaluations have indicated that selected vaginal
applicants alter the composition of VMB [20]. Therefore, we
sought to evaluate the impact of a single dose of the FDAapproved antiretroviral TFV delivered to colonized cultures just
prior to HIV-1 challenge. The results showed that TFV-treated
cultures had reduced HIV-1 burdens relative to untreated cultures
(Fig. 4A, blue versus white bars). As a measure of efficacy, we
calculated the percentage of HIV-1 genome reduction by dividing
the difference in HIV-1 load in TFV-treated and untreated
cultures by the average HIV-1 burden in the untreated cultures
(Fig. 4A, red bars). Although not significantly different, there was a
trend indicating reduced TFV efficacy in the cultures colonized by
the HIV-1 enhancing VMB relative to those with suppressing
communities. Specifically, the CST III VMB that was most
suppressive had a 99% reduction in HIV-1 burden following TFV
treatment. The CST IVB community that increased HIV-1 titers
most significantly, had only an average 37% reduction in HIV-1
after TFV. This level of efficacy was similar to uncolonized TFVtreated cultures. The lowest TFV efficacy, only 25% reduction in
HIV-1, was observed in the CST IVA community that had similar
HIV-1 enhancement to the IVB community.
A limited preliminary study of the impact of TFV upon VMB
composition was completed to determine if the colonized coculture system could be used to complete in vitro assessments of
potential VMB toxicity. For this evaluation the profiles of the
suppressing CST III VMB from a pool of three cultures treated
with TFV or three parallel cultures that were treated with vehicle
alone were compared (Fig. 4B). Similarly, the HIV-1 enhancing
CST IVB community also was assessed (Fig. 4C). Consistent with
studies by members of our team that indicated biofilm formation
and thickness on the surface of emplaced intravaginal rings (IVR)
were not generally altered by TFV [41], the overall bacterial load
in colonized co-cultures for both CST VMBs was not significantly
different in the presence or absence of TFV. Further, as generally
observed in the CAPRISA 004 data sets and early topical TFV
safety testing [42,43], the levels of total Lactobacilli were
maintained or reduced by ,10 fold by TFV application.
Interestingly, individual Lactobacilli species were substantially
reduced in number in the suppressive CST III VMB (Fig. 4B, red
bars, ,100 fold) suggesting Lactobacilli species not included in our
qPCR assays were increased. Reductions in levels of other bacteria
in the CST III VMB included Acidovorax, Corynebacterium,
Haemophilus, Prevotella spp, total Streptococcus and total Enterococcus. A complete loss of Corynebacterium was observed in the
TFV-treated CST IVB cultures. Reductions in total Enterococcus
also were observed as were a number of additional bacteria
common to the CST IVB community including Dialister, S.
sanguinegens, Peptostreptococcus spp, total Staphylococcus, Eggerthella spp
and Veillonella spp. TFV treatment increased a few bacteria types
within each community but generally to a lesser degree than seen
with the reductions. In the CST IVB community, a single
PLOS ONE | www.plosone.org
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Figure 4. TFV efficacy was altered by representative VMB colonization and impacted the composition of VMB. Panel A depicts the
anti-HIV-1 efficacy of TFV in VEC/TZM-bl cultures (N = 3) colonized as indicated with representative VMB. The white bars indicate HIV-1 titers in
untreated parallel cultures and confirm the previous results (Fig. 3). The presence of TFV (blue bars) consistently reduced the numbers of viral
genomes but, as shown in the red bars, a non-significant trend indicated that the level of reduction was VMB-dependent. Panels B and C,
respectively, depict the most suppressive and most enhancing VMB community profiles in the absence (white bars) or presence (blue bars) of TFV
(N = 2 cultures/condition). The fold change in detected bacterial genomes associated with TFV application is shown for each of the selected
organisms as a loss (red bar on left of the vertical axis) or gain (right of axis) in number relative to the untreated cultures.
doi:10.1371/journal.pone.0093419.g004

metabolome and proteome of vaginal fluids collected from women
before and after treatment for BV that identified a number of
metabolic markers and signaling molecules associated with BV
[45,46]. Controlled addition of specific immune cells in the
context of selected colonization should help advance these types of
studies in the future.
The established co-cultures also allow for study of STI outcomes
in the context of the VMB including life-threatening HIV-1
transmission and infection as described in this report. It has been
estimated that HIV-1 infection requires 200–2,000 exposures to
virus during vaginal intercourse but during BV episodes and
coincident inflammation in the vaginal mucosa the risk of HIV-1
transmission is significantly increased [21,47]. Clinical associations
have established that these time periods include significantly
elevated levels of pro-inflammatory cytokines including TNFa, IL1b, IL-6 and IL-8 [48,49]. Consistent with these clinical findings,
the VEC co-cultures colonized with intermediate or high NS
VMB of CST III or IVB led to significantly elevated production of
IL-1b, IL-8, TNFa, as well as RANTES and IL-1ra (Table 2). IL-6
trended higher in both community types but was not significantly
different than uncolonized cultures. These data are in line with a
clinical study that concluded IL-8 but not IL-1b or IL-6 were
associated with BV [50]. Coincident with these elevated levels, we
found that these communities led to higher HIV-1 burden and
reduced efficacy of a single application of TFV (Fig. 3 & 4). Similar
cytokines are elevated by several failed vaginally-applied candidate
microbicides including nonoxynol-9 and cellulose sulfate that led
to increased susceptibility to HIV-1 infection [20,28]. In the
culture system, elevation of these cytokines likely led to an
PLOS ONE | www.plosone.org

activated state in the MDM more favorable for HIV-1 replication
but additional research will be required to establish the mechanism
for the enhanced or suppressed HIV-1 outcomes.
The application of next generation sequencing has also recently
shown that the vaginal application of candidate microbicides and
other products altered the composition of the VMB of treated
women. These studies mark the beginning of improved toxicity
screening of candidate compounds but are expensive, laborintensive and rely upon clinical materials emphasizing the need for
a model system capable of screening vaginally-applied compounds
for impact on the VMB prior to clinical evaluation. As proof of
concept, we tested the impact of a single application of TFV upon
HIV-1 in the context of colonized cultures and also assessed the
community changes (Fig. 4). Although limited in scope, the data
indicated that the efficacy of TFV was reduced by some of the
selected VMB community members. Another limitation of our
approach was the use of qPCR assessment of the VMB
composition limiting the list of bacteria studied to those targeted
by the assays. Clearly there are bacteria that are not accounted for
that would be identified by the more costly and labor intensive
next generation sequencing approaches. Additional studies will be
required to complete the analyses of TFV but the current data
indicate the potential utility of the system.
Recent clinical trials of topical vaginal microbicides designed to
reduce HIV-1 transmission including CAPRISA 004 have shown
the potential of a TFV gel formulation. The impact of vaginallyapplied 1% TFV gel on VMB community composition has not
been reported but in clinical trials that included assessment of the
microflora there were indications of altered community profiles
9
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culture system and to create data sets that showed the
reproducibility and consistency of VMB colonization from
cryopreserved clinical material. The second phase of the study
design was undertaken to establish the impact of selected CST
representative VMBs upon HIV-1 replication in the refined VEC
co-culture models. The resulting culture system also provided
preliminary data for the impact of a single dose of TFV on HIV-1
replication and on the representative VMB community composition. Collectively, the data show that the culture system provided
an effective environment to support colonization by the diverse
and highly complex bacterial communities associated with both
health and dysbiotic BV states. Controlled replicate cultures were
established to study the VMB effect upon HIV-1 infection
independent of host genetics, hormonal or environmental factors,
yeast, the presence of other STI or genital pathogen or by the
natural fluctuations of the VMB observed in recent cultivationindependent evaluations. The presented data represent results
from studies in VEC from a single genetic background under
highly controlled conditions but have been completed in limited
fashion in two additional cultures with similar outcomes.

based on Nugent scoring [43]. No significant differences in BVrelated symptoms (e.g. vaginal discharge) were reported between
TFV-treated and placebo groups [42,43]. Consistent with these
outcomes, a single application of TFV in our culture system led to
disruption of the community profile for both the healthy and BV
VMB selected for evaluation (Fig. 4). In both of the analyzed VMB
the overall bacterial load was generally preserved but loss of
distinct species and overgrowth by others was noted (Fig. 4). Deep
sequencing data sets from clinical samples representing TFV
treated versus placebo controls are needed to validate the
predictions of the culture data but are consistent with the changes
in reported NSs [43]. The data from the culture system lack the
confounders associated with clinical sampling and strongly support
additional evaluations of vaginal applicants for impact upon the
VMB prior to clinical trials.
The culture system also provides the first opportunity to study
bacterial interactions, products and signaling during the formation
of the pathogenic biofilms associated with BV. Other cell culture
models have been used to evaluate the initial adhesion and
potential order of introduction of bacterial species that overwhelm
otherwise healthy VMBs [51,52]. Reports from the human vaginal
microbiome center and collaborating researchers have shown how
BV-associated bacterial species that can be cultivated in the lab
adhere to HeLa or ME-180 cell line derived from cervical cancers
[51,52]. These recent reports suggest that G. vaginalis is an initial
colonizer setting up for more damaging VMB and biofilm
formation [51,52]. Although these study designs lack the intact
VMB and impact of existing partnerships on colonization order,
they provide advantages of data created from evaluation of
individual species. A limitation of our current study is the
composition of the clinical VMB that we have selected and the
limited numbers of species represented. We previous reported
colonization of VEC multilayer cultures with selected single
Lactobacillus species or other bacteria common to the vagina
showing that commensal bacteria associated with health tempered
innate immune responses [36].
The VEC multilayer model also provided three compartments
that each represent specific aspects of vaginal tissue as well as
support of study of the HIV-1 infection cycle. Using HPV E6/E7
oncoprotein immortalized rather than cancerous cells has provided the opportunity for expanded numbers of available cells of the
same genetic background without the issues associated with
oncogenic transformation. The immortalization process does alter
the cell’s physiology but the expansion limitations and difficulties
associated with tissue procurement to create primary cells require
the use of such cell cultures for initial screens. Subsequent
confirmation studies with cryopreserved primary progenitors are
warranted for some candidate evaluations.
During our foundational evaluations of the culture system we
intentionally avoided the addition of exogenous hormones
essentially modeling the transition between the luteal and follicular
phase with the VEC co-cultures. Future work will include the
addition of progesterone and/or estrogen to reflect levels
associated with specific stages of the menstrual cycle. Subsequent
studies will allow for the evaluation of components of seminal fluid,
over the counter vaginal applicants and ultimately provide a
system to evaluate the potential toxicity of candidate compounds
and probiotics.

Cell culture
Immortalized V19I VEC were cultured as described previously
[36,53]. TZM-bl cells are a HeLa-derived, genetically engineered
HIV-1-susceptible cell line that provided the advantage of a bgalactosidase (b-gal) reporter system induced by HIV-1 Tat. TZMbl cells were obtained through the AIDS Research and Reference
Reagent Program, Division of AIDS, NIAID, and NIH, from Drs.
Kappes and Wu and Tranzyme Inc. [39] and were cultured as
described [37,38]. Monocyte-derived macrophages (MDM) were
established from peripheral blood collected from healthy volunteers with full IRB approval as previously described [53]. For these
studies data from a single donor are presented but were consistent
across four distinct donors. Fully mature MDM were differentiated
within 7 d of conditioning and were harvested in parallel to VEC
for establishment of co-cultures. Co-cultures were created by
mixing VEC with the selected HIV-1-susceptible cell type at a
ratio of 1,000 VEC to 1 HIV susceptible cell just prior to plating in
transwells. For the 96 well transwell format (BD Falcon; Franklin
Lakes, NJ), 105 cells were plated while 106 cells were plated in 24
well format transwells (Greiner Bio One; Monroe, NC). Each
culture was allowed to stabilize at 37uC, 5% CO2 for 16 h before
the apical medium was removed to create the air-interface. Basal
chambers were refed with antibiotic-free medium every other day
as described [36]. Cultures had fully formed multilayers within 7–
9 d.

Single species and VMB community preparation and
application
Indicated bacterial strains were cultured as described [36] and
added at 103 in phosphate-buffered saline (PBS) after extensive
washing to remove the bacterial medium. Inocula were either
50 ml for a 24 transwell or 10 ml for a 96 well transwell. Clinical
samples were diluted in sterile PBS based on the total bacterial
genomic titer in the clinical sample as determined by 16S rDNA
PCR.
To collect VMB, healthy women undergoing routine gynecological examinations were informed of the scope of the study and
with their consent were sampled by gentle rubbing of a sterile
calcium alginate swab on a mid vaginal wall location. Vaginal
swabs were immediately placed into sterile PBS and transported to
the processing lab on ice. All work was completed with care to
protect the identity of the patient with full approval of the UTMB
IRB. Vaginal samples were aliquoted for standard DNA extraction

Materials and Methods
Overall study design
The goal of the designed studies was two-fold. The first
experiments were completed to establish the potential of the VEC
PLOS ONE | www.plosone.org
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and cryopreservation in a sterile glycerol solution before storage at
280C. Molecular evaluations of the VMB composition were
completed by PCR (Table 1 and Table S1) targeting 40 relevant
species.
Bacterial viability was quantified by addition of 10 ul of the
inoculum to 90 ul Mann-Ragosa Sharpe (MRS) broth (BD Falcon)
followed by serial 10-fold dilution and culture at 37uC for 48 h.
Bacterial growth in each dilution was assessed and allowed for
estimation of the viable titers of bacteria that were supported by
this broth culture.

DAPI (Vector Labs, Burlingame, CA) before imaging on a Nikon
Eclipse Ti, Nikon. Scanning electron microscopy was completed as
previously described [36]. Briefly, fixed cultures were dehydrated
in ethanol and processed through hexamethyldisalazane followed
by air-drying before mounting onto metal stubs and sputter-coated
with iridium in an Emitech K575x Sputter Coater (Emitech,
Houston, TX) at 20 mA for 20 sec. The filters were examined in a
Hitachi S4700 SEM (Hitachi High Technologies, Schaumburg,
IL) at 2 kV.

Cytokine quantification

Ethics Statement

Triplicate mature multilayer cultures were harvested 48 h after
application of L. crispatus or the indicated VMBs (Table 2) and
compared to uncolonized control cultures processed in parallel as
previously described (36). Briefly, the cell layer was scraped into a
commercial lysis solution (Bio-Rad) and processed following the
instructions for the human 27-plex kit (BioPlex, Bio-Rad).
Approximately 1/3 of the cell fraction was analyzed and the
entire study was independently repeated providing average
cytokine levels for 6 distinct cultures.

Collection of VMB samples and creation of MDM populations
from venous blood collected from health volunteers was complete
with the full approval of the University of Texas Medical Branch’s
institutional review board. Only adult subjects were enrolled in the
study and provided written informed consent prior to collection of
materials.

HIV-1 infection, titer determination and tenofovir (TFV)
efficacy
HIV-1 (1,000 TCID50) was added to multilayer cultures 16 h
after colonization by the indicated bacterial strains or VMB
communities. A titered stock of HIV-1SX-1 a chimeric M-tropic
virus (R5) encoding the majority of the HIV-1JRFL envelope
protein in an HIV-1NL4-3 backbone (purchased from the Virology
Core Facility, Center for AIDS Research at Baylor College of
Medicine, Houston, TX) was diluted to create an MOI of 1
relative to the susceptible cells in the co-culture [53]. TFV (a gift of
Oak Crest Institute of Science) was prepared as a 1 uM stock in
VEC culture medium and applied as a 10 ul apical or 25 ul basal
dose designed to deliver 106 the in vitro IC50 [54]. TFV
application was 10 minutes prior to challenge with HIV-1 and
24 h after VMB colonization. Infected multilayer cultures were
incubated at 37uC for up to 72 h and sampled as indicated. Apical
samples were harvested by gently washing the surface of each
culture with 100 ml of PBS with a sterile pipet. Cell layers were
scraped into 200 ul of a lysis solution compatible with protein
analysis or nucleic acid extraction. Basal medium was collected by
sterile pipet and mixed with protein or nucleic acid extraction
solutions. RNA was purified with an Aurum 96 extraction system
(Bio-Rad, Hercules, CA). DNA was extracted by magnetic particle
systems from Thermo-Kingfisher (ThermoFisher Scientific, Waltham, MA) in 96 well format on a BioSprint automated extraction
system (Qiagen, Valencia, CA).

Statistics
All experiments with the exception of those presented in Fig. 4,
were completed at least three times with each condition
represented as at least a triplicate within an individual study.
Mean values are presented with SEM values. N indicates the
number of biological replicates in each study. Most data were
evaluated using ANOVA tests with Bonferroni’s or Dunnett’s
multiple comparison corrections as indicated in the figure legends.
A P-value of ,0.05 was considered to be significant and is
indicated by a * or # symbol in the figures. All statistical
evaluations were completed with Prism software (v6.0; GraphPad,
San Diego, CA).

Supporting Information
Table S1 PCR target data for the analysis of the VMB.
Sequences for the primers utilized for the quantification of bacteria
present in the clinical and lab-based samples are shown along with
associated source references as indicated in the far right column.
The VMB-target, GenBank accession number and the name of
the target gene are provided for each of the bacterial targets
included in the array.
(DOCX)

Acknowledgments

Microscopic evaluations of multilayers and VMB
For histology and immunolabeling studies, multilayers were
fixed in 2% formaldehyde for 10 minutes at 4uC, then washed
with PBS. Wells were then incubated with X-Gal buffer [55]
containing X-Gal (1 mg/ml) for 48 h at 37uC then washed with
PBS before photomicroscopy was performed. For standard
histological staining, membranes, removed from the transwell
insert using a scalpel, were embedded in paraffin and then
sectioned (6 um) and stained with hematoxylin and eosin before
being imaged [36]. Immunofluorescent labeling for specific
proteins was performed using an anti-human CD4 antibody
(BD). Labeled sections were cover slipped with hard set containing

We thank the NIH AIDS Research and Reference Reagent Program for
providing the TZM-bl cells. We thank Edward Siwak, Ph.D., Associate
Director of Virology Core Facility, Center for AIDS Research at Baylor
College of Medicine, Houston, TX for providing HIV-1sx.

Author Contributions
Conceived and designed the experiments: RBP KLV MMB TDEP MRF.
Performed the experiments: RBP ALM BE CM GL VLP RJN. Analyzed
the data: RBP KLV MMB TDEP MRF. Contributed reagents/materials/
analysis tools: RBP KLV TDEP. Wrote the paper: RBP MMB TDEP
MRF.

References
1. Thomas S (1928) Doderlein’s bacillus - Lactobacillus acidophilus. Journal of
Infectious Diseases 43: 218–227.
2. Weinstein L, Howard JH (1937) The Incidence of the Doderlein Vaginal
Bacillus During the Post-Climacterium. Yale J Biol Med 10: 185–190.

PLOS ONE | www.plosone.org

3. Sobel JD (2005) What’s new in bacterial vaginosis and trichomoniasis? Infect Dis
Clin North Am 19: 387–406.
4. Koumans EH, Sternberg M, Bruce C, McQuillan G, Kendrick J, et al. (2007)
The prevalence of bacterial vaginosis in the United States, 2001–2004;

11

March 2014 | Volume 9 | Issue 3 | e93419

Cultivated Vaginal Microbiomes Alter HIV-1 Infection

5.
6.
7.

8.

9.

10.

11.

12.

13.

14.

15.

16.

17.

18.
19.

20.
21.

22.
23.

24.

25.

26.

27.

28.

29.

30.

associations with symptoms, sexual behaviors, and reproductive health. Sex
Transm Dis 34: 864–869.
Kenyon C, Colebunders R, Crucitti T (2013) The global epidemiology of
bacterial vaginosis: a systematic review. Am J Obstet Gynecol.
Pennock JW, Stegall R, Bell B, Vargas G, Motamedi M, et al. (2009) Estradiol
improves genital herpes vaccine efficacy in mice. Vaccine 27: 5830–5836.
Fethers KA, Fairley CK, Hocking JS, Gurrin LC, Bradshaw CS (2008) Sexual
risk factors and bacterial vaginosis: a systematic review and meta-analysis. Clin
Infect Dis 47: 1426–1435.
Verstraelen H, Swidsinski A (2013) The biofilm in bacterial vaginosis:
implications for epidemiology, diagnosis and treatment. Curr Opin Infect Dis
26: 86–89.
Verstraelen H, Verhelst R, Vaneechoutte M, Temmerman M (2010) The
epidemiology of bacterial vaginosis in relation to sexual behaviour. BMC Infect
Dis 10: 81.
Vincent KL, Vargas G, Wei J, Bourne N, Motamedi M (2013) Monitoring
vaginal epithelial thickness changes noninvasively in sheep using optical
coherence tomography. Am J Obstet Gynecol 208: 282 e281–287.
Milligan GN, Meador MG, Chu CF, Young CG, Martin TL, et al. (2005) Longterm presence of virus-specific plasma cells in sensory ganglia and spinal cord
following intravaginal inoculation of herpes simplex virus type 2. J Virol 79:
11537–11540.
Brotman RM, Klebanoff MA, Nansel TR, Andrews WW, Schwebke JR, et al.
(2008) A longitudinal study of vaginal douching and bacterial vaginosis–a
marginal structural modeling analysis. Am J Epidemiol 168: 188–196.
Bird MD, Chu CF, Johnson AJ, Milligan GN (2007) Early resolution of herpes
simplex virus type 2 infection of the murine genital tract involves stimulation of
genital parenchymal cells by gamma interferon. J Virol 81: 423–426.
Petrova MI, van den Broek M, Balzarini J, Vanderleyden J, Lebeer S (2013)
Vaginal microbiota and its role in HIV transmission and infection. FEMS
Microbiol Rev 37: 762–792.
Martin HL, Richardson BA, Nyange PM, Lavreys L, Hillier SL, et al. (1999)
Vaginal lactobacilli, microbial flora, and risk of human immunodeficiency virus
type 1 and sexually transmitted disease acquisition. J Infect Dis 180: 1863–1868.
Sha BE, Zariffard MR, Wang QJ, Chen HY, Bremer J, et al. (2005) Female
genital-tract HIV load correlates inversely with Lactobacillus species but
positively with bacterial vaginosis and Mycoplasma hominis. J Infect Dis 191:
25–32.
Cohen CR, Lingappa JR, Baeten JM, Ngayo MO, Spiegel CA, et al. (2012)
Bacterial vaginosis associated with increased risk of female-to-male HIV-1
transmission: a prospective cohort analysis among African couples. PLoS Med 9:
e1001251.
Hemelaar J, Gouws E, Ghys PD, Osmanov S (2011) Global trends in molecular
epidemiology of HIV-1 during 2000–2007. AIDS 25: 679–689.
Wahren B, Biswas P, Borggren M, Coleman A, Da Costa K, et al. (2010)
Rational design of HIV vaccine and microbicides: report of the EUROPRISE
annual conference. J Transl Med 8: 72.
Ravel J, Gajer P, Fu L, Mauck CK, Koenig SS, et al. (2012) Twice-daily
application of HIV microbicides alter the vaginal microbiota. MBio 3.
Schellenberg JJ, Plummer FA (2012) The Microbiological Context of HIV
Resistance: Vaginal Microbiota and Mucosal Inflammation at the Viral Point of
Entry. Int J Inflam 2012: 131243.
Shattock RJ, Rosenberg Z (2012) Microbicides: topical prevention against HIV.
Cold Spring Harb Perspect Med 2: a007385.
Ramjee G, Morar NS, Braunstein S, Friedland B, Jones H, et al. (2007)
Acceptability of Carraguard, a candidate microbicide and methyl cellulose
placebo vaginal gels among HIV-positive women and men in Durban, South
Africa. AIDS Res Ther 4: 20.
Van Damme L, Govinden R, Mirembe FM, Guedou F, Solomon S, et al. (2008)
Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV
transmission. N Engl J Med 359: 463–472.
Cone RA, Hoen T, Wong X, Abusuwwa R, Anderson DJ, et al. (2006) Vaginal
microbicides: detecting toxicities in vivo that paradoxically increase pathogen
transmission. BMC Infect Dis 6: 90.
Keller MJ, Carpenter CA, Lo Y, Einstein MH, Liu C, et al. (2012) Phase I
randomized safety study of twice daily dosing of acidform vaginal gel: candidate
antimicrobial contraceptive. PLoS One 7: e46901.
Mirmonsef P, Gilbert D, Zariffard MR, Hamaker BR, Kaur A, et al. (2011) The
effects of commensal bacteria on innate immune responses in the female genital
tract. Am J Reprod Immunol 65: 190–195.
Fichorova RN, Tucker LD, Anderson DJ (2001) The molecular basis of
nonoxynol-9-induced vaginal inflammation and its possible relevance to human
immunodeficiency virus type 1 transmission. J Infect Dis 184: 418–428.
Pirrone V, Wigdahl B, Krebs FC (2011) The rise and fall of polyanionic
inhibitors of the human immunodeficiency virus type 1. Antiviral Res 90: 168–
182.
Segarra TJ, Fakioglu E, Cheshenko N, Wilson SS, Mesquita PM, et al. (2011)
Bridging the gap between preclinical and clinical microbicide trials: blind
evaluation of candidate gels in murine models of efficacy and safety. PLoS One
6: e27675.

PLOS ONE | www.plosone.org

31. Hummelen R, Fernandes AD, Macklaim JM, Dickson RJ, Changalucha J, et al.
(2010) Deep sequencing of the vaginal microbiota of women with HIV. PLoS
One 5: e12078.
32. Lambert JA, Kalra A, Dodge CT, John S, Sobel JD, et al. (2013) Novel PCRbased methods enhance characterization of vaginal microbiota in a bacterial
vaginosis patient before and after treatment. Appl Environ Microbiol 79: 4181–
4185.
33. Gajer P, Brotman RM, Bai G, Sakamoto J, Schutte UM, et al. (2012) Temporal
dynamics of the human vaginal microbiota. Sci Transl Med 4: 132ra152.
34. Ravel J, Gajer P, Abdo Z, Schneider GM, Koenig SS, et al. (2011) Vaginal
microbiome of reproductive-age women. Proc Natl Acad Sci U S A 108 Suppl 1:
4680–4687.
35. Srinivasan S, Hoffman NG, Morgan MT, Matsen FA, Fiedler TL, et al. (2012)
Bacterial communities in women with bacterial vaginosis: high resolution
phylogenetic analyses reveal relationships of microbiota to clinical criteria. PLoS
One 7: e37818.
36. Rose WA Jr, McGowin CL, Spagnuolo RA, Eaves-Pyles TD, Popov VL, et al.
(2012) Commensal bacteria modulate innate immune responses of vaginal
epithelial cell multilayer cultures. PLoS One 7: e32728.
37. Moss JA, Malone AM, Smith TJ, Butkyavichene I, Cortez C, et al. (2012) Safety
and pharmacokinetics of intravaginal rings delivering tenofovir in pig-tailed
macaques. Antimicrob Agents Chemother 56: 5952–5960.
38. Eaves-Pyles T, Patel J, Arigi E, Cong Y, Cao A, et al. (2013) Immunomodulatory
and Antibacterial Effects of Cystatin 9 against Francisella tularensis. Mol Med
19: 263–275.
39. Takeuchi Y, McClure MO, Pizzato M (2008) Identification of gammaretroviruses constitutively released from cell lines used for human immunodeficiency
virus research. J Virol 82: 12585–12588.
40. Givan AL, White HD, Stern JE, Colby E, Gosselin EJ, et al. (1997) Flow
cytometric analysis of leukocytes in the human female reproductive tract:
comparison of fallopian tube, uterus, cervix, and vagina. Am J Reprod Immunol
38: 350–359.
41. Johnson AJ, Chu CF, Milligan GN (2008) Effector CD4+ T-cell involvement in
clearance of infectious herpes simplex virus type 1 from sensory ganglia and
spinal cords. J Virol 82: 9678–9688.
42. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, et al.
(2010) Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for
the prevention of HIV infection in women. Science 329: 1168–1174.
43. Mayer KH, Maslankowski LA, Gai F, El-Sadr WM, Justman J, et al. (2006)
Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active
HIV-infected and uninfected women. AIDS 20: 543–551.
44. Hickey RJ, Zhou X, Pierson JD, Ravel J, Forney LJ (2012) Understanding
vaginal microbiome complexity from an ecological perspective. Transl Res 160:
267–282.
45. Chu CF, Meador MG, Young CG, Strasser JE, Bourne N, et al. (2008)
Antibody-mediated protection against genital herpes simplex virus type 2 disease
in mice by Fc gamma receptor-dependent and -independent mechanisms.
J Reprod Immunol 78: 58–67.
46. Yeoman CJ, Thomas SM, Miller ME, Ulanov AV, Torralba M, et al. (2013) A
multi-omic systems-based approach reveals metabolic markers of bacterial
vaginosis and insight into the disease. PLoS One 8: e56111.
47. Boily MC, Baggaley RF, Wang L, Masse B, White RG, et al. (2009)
Heterosexual risk of HIV-1 infection per sexual act: systematic review and
meta-analysis of observational studies. Lancet Infect Dis 9: 118–129.
48. Spear GT, St John E, Zariffard MR (2007) Bacterial vaginosis and human
immunodeficiency virus infection. AIDS Res Ther 4: 25.
49. Nies AT, Damme K, Schaeffeler E, Schwab M (2012) Multidrug and toxin
extrusion proteins as transporters of antimicrobial drugs. Expert Opin Drug
Metab Toxicol 8: 1565–1577.
50. Losikoff P, Fichorova R, Snyder B, Rodriguez I, Cu-Uvin S, et al. (2007) Genital
tract interleukin-8 but not interleukin-1beta or interleukin-6 concentration is
associated with bacterial vaginosis and its clearance in HIV-infected and HIVuninfected women. Infect Dis Obstet Gynecol 2007: 92307.
51. Baum MM, Butkyavichene I, Gilman J, Kennedy S, Kopin E, et al. (2012) An
intravaginal ring for the simultaneous delivery of multiple drugs. J Pharm Sci
101: 2833–2843.
52. Moss JA, Malone AM, Smith TJ, Kennedy S, Kopin E, et al. (2012)
Simultaneous delivery of tenofovir and acyclovir via an intravaginal ring.
Antimicrob Agents Chemother 56: 875–882.
53. Bell BA, Vincent KL, Bourne N, Vargas G, Motamedi M (2013) Optical
coherence tomography for assessment of microbicide safety in a small animal
model. J Biomed Opt 18: 046010.
54. Palmer S, Margot N, Gilbert H, Shaw N, Buckheit R Jr, et al. (2001) Tenofovir,
adefovir, and zidovudine susceptibilities of primary human immunodeficiency
virus type 1 isolates with non-B subtypes or nucleoside resistance. AIDS Res
Hum Retroviruses 17: 1167–1173.
55. Pyles RB, Thompson RL (1994) Mutations in accessory DNA replicating
functions alter the relative mutation frequency of herpes simplex virus type 1
strains in cultured murine cells. J Virol 68: 4514–4524.

12

March 2014 | Volume 9 | Issue 3 | e93419

